Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,571.93 +3,447.53 (+5.83%) CMC Crypto 200
1,363.86 +86.88 (+6.80%)
Trevi Therapeutics, Inc. (TRVI)
After hours:
| Previous close | 3.0100 |
| Open | 3.0200 |
| Bid | 3.0100 x 200 |
| Ask | 3.0400 x 200 |
| Day's range | 2.9800 - 3.1200 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 304,045 |
| Market cap | 212.714M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- Zacks
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Insider Monkey
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript March 20, 2024 Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the […]
